Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from July 24, 2025

Partial Published before the outcome was known, scored automatically when the window closed on October 22, 2025.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$66.00 – $67.47Entry zone — fair-value band

$69.25Published — price the day we called it

$82.17Target — the price the thesis aimed for

$71.00Peak — highest point inside the window, not a realized return

$53.38Window close — end-of-window price, context only

What happened

Partial

Reached 13% of the predicted growth at its peak, without hitting the target.

Peak price

$71.00

peak on July 25, 2025 — not a realized return

Peak gain

+2.5%

peak, from the publication price

Window close

$53.38

end-of-window price, context only

Days to target

—

Window

July 24, 2025 – October 22, 2025

The thesis — published July 24, 2025

Predicted growth

+20%

over the measurement window

Target price

$82.17

the price the thesis aimed for

Entry zone

$66.00 – $67.47

the fair-value band we waited for

Price at publication

$69.25

published July 24, 2025

Confidence

77%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Sales of its key diabetes and weight-loss drugs are running 45% above last year, and a major parts supplier just said orders are even stronger than they expected. The share price has been resting in a tight range after the recent split, while investors digest chatter about possible tariffs and wait for new supply details later in August. If the company confirms it can ship enough medicine, the price could climb toward $84, about 20% higher, over the next few months.

Primary drivers

Sales of GLP-1 drugs up 45%, and the pool of potential obesity patients is widening worldwide.
Key supplier raised its forecast, proving the factories are ordering more parts.
Steady upward trading with small daily swings shows investors are quietly adding shares.
Tight price range hints at a bigger move ahead when tariff worries fade.

How it played out

NVO: the thesis missed the target

Lyra published NVO at $69.25 on 2025-07-24 with a short-term thesis for 20% growth. The thesis pointed to GLP-1 sales up 45%, stronger supplier orders, steady upward trading with small daily swings, and a tight price range that could break higher if tariff worries faded and supply details improved.

Inside the window, the stock peaked at $71 on 2025-07-25, a 2.5% gain. It stayed below the $82.17 target and never reached it. By 2025-10-22, it ended at $53.38. The published thesis did not play out.

What happened during the window

On 2025-07-29, Novo Nordisk cut its 2025 sales growth outlook to 8% to 14% and named Maziar Mike Doustdar as CEO effective 2025-08-07. On 2025-09-10, the company announced a restructuring with 9,000 job cuts and a lower 2025 profit forecast.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals